Global Lung Cancer Screening Software Market

Lung Cancer Screening Software Comprehensive Study by Enterprise (Small and Medium Enterprises, Large Enterprises), Deployment (Cloud-Based, On-Premises), Subscription (Monthly, Annual, Quarterly, Permanent) Players and Region - Global Market Outlook to 2030

Lung Cancer Screening Software Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Lung Cancer Screening Software
Lung cancer screening is a process used for the detection of the presence of lung cancer in otherwise healthy people with a high risk of lung cancer. Lung cancer screening software is designed to automate the workflow of healthcare facilities by tracking patients from screening follow-up and beyond, track incidental pulmonary nodules and others.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Lung Cancer Screening Software market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

PenRad Technologies, Inc. (United States), Koninklijke Philips N.V. (Netherlands), Kheiron Medical Technologies (United Kingdom), Volpara Solutions Limited (New Zeland), Thynk Health (United States), CRA Health LLC (United States), ProVation Medical, Inc. (United States), Nuance Communications, Inc. (United States), Siemens Healthcare GmbH (Germany) and CureMetrix, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are MobileODT (Israel), Vital Images, Inc (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Lung Cancer Screening Software market by and Region.



On the basis of geography, the market of Lung Cancer Screening Software has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Enterprise, the sub-segment i.e. Small and Medium Enterprises will boost the Lung Cancer Screening Software market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Deployment, the sub-segment i.e. Cloud-Based will boost the Lung Cancer Screening Software market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Subscription, the sub-segment i.e. Monthly will boost the Lung Cancer Screening Software market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Awareness about Cancer Screening among People and Increased Adoption of Cloud-Based Solutions

Market Growth Drivers:
Increased Prevalence of Lung Cancer, Increased Diagnostic Centres and Hospitals and Government Initiatives for Cancer Screening Programs

Challenges:
Privacy and Security Issues Associated with Patient Data and Lack of Funding

Restraints:
Technological Complexities associated with Software and Lack of Skilled Professionals in Some Regions

Opportunities:
Growing Healthcare Industry Worldwide and New Advancements in the Medical Science

Market Leaders and their expansionary development strategies
In November 2022, RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today reported it has acquired a 75% interest in London-based Heart & Lung Imaging Limited (“Heart&Lung Health” or “HLH”).
In October 2023, DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, announced the initial commercial introduction of FirstLook Lung. FirstLook is a blood test that offers a convenient, accurate and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT), with a negative predictive value (NPV) of 99.7 percent.


Key Target Audience
Lung Cancer Screening Software Developers, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Enterprise
  • Small and Medium Enterprises
  • Large Enterprises

By Deployment
  • Cloud-Based
  • On-Premises

By Subscription
  • Monthly
  • Annual
  • Quarterly
  • Permanent

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Lung Cancer
      • 3.2.2. Increased Diagnostic Centres and Hospitals
      • 3.2.3. Government Initiatives for Cancer Screening Programs
    • 3.3. Market Challenges
      • 3.3.1. Privacy and Security Issues Associated with Patient Data
      • 3.3.2. Lack of Funding
    • 3.4. Market Trends
      • 3.4.1. Growing Awareness about Cancer Screening among People
      • 3.4.2. Increased Adoption of Cloud-Based Solutions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lung Cancer Screening Software, by Enterprise, Deployment, Subscription and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lung Cancer Screening Software (Value)
      • 5.2.1. Global Lung Cancer Screening Software by: Enterprise (Value)
        • 5.2.1.1. Small and Medium Enterprises
        • 5.2.1.2. Large Enterprises
      • 5.2.2. Global Lung Cancer Screening Software by: Deployment (Value)
        • 5.2.2.1. Cloud-Based
        • 5.2.2.2. On-Premises
      • 5.2.3. Global Lung Cancer Screening Software by: Subscription (Value)
        • 5.2.3.1. Monthly
        • 5.2.3.2. Annual
        • 5.2.3.3. Quarterly
        • 5.2.3.4. Permanent
      • 5.2.4. Global Lung Cancer Screening Software Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Lung Cancer Screening Software (Price)
  • 6. Lung Cancer Screening Software: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. PenRad Technologies, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Koninklijke Philips N.V. (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Kheiron Medical Technologies (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Volpara Solutions Limited (New Zeland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thynk Health (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CRA Health LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ProVation Medical, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Nuance Communications, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Siemens Healthcare GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CureMetrix, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Lung Cancer Screening Software Sale, by Enterprise, Deployment, Subscription and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lung Cancer Screening Software (Value)
      • 7.2.1. Global Lung Cancer Screening Software by: Enterprise (Value)
        • 7.2.1.1. Small and Medium Enterprises
        • 7.2.1.2. Large Enterprises
      • 7.2.2. Global Lung Cancer Screening Software by: Deployment (Value)
        • 7.2.2.1. Cloud-Based
        • 7.2.2.2. On-Premises
      • 7.2.3. Global Lung Cancer Screening Software by: Subscription (Value)
        • 7.2.3.1. Monthly
        • 7.2.3.2. Annual
        • 7.2.3.3. Quarterly
        • 7.2.3.4. Permanent
      • 7.2.4. Global Lung Cancer Screening Software Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Lung Cancer Screening Software (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lung Cancer Screening Software: by Enterprise(USD Million)
  • Table 2. Lung Cancer Screening Software Small and Medium Enterprises , by Region USD Million (2018-2023)
  • Table 3. Lung Cancer Screening Software Large Enterprises , by Region USD Million (2018-2023)
  • Table 4. Lung Cancer Screening Software: by Deployment(USD Million)
  • Table 5. Lung Cancer Screening Software Cloud-Based , by Region USD Million (2018-2023)
  • Table 6. Lung Cancer Screening Software On-Premises , by Region USD Million (2018-2023)
  • Table 7. Lung Cancer Screening Software: by Subscription(USD Million)
  • Table 8. Lung Cancer Screening Software Monthly , by Region USD Million (2018-2023)
  • Table 9. Lung Cancer Screening Software Annual , by Region USD Million (2018-2023)
  • Table 10. Lung Cancer Screening Software Quarterly , by Region USD Million (2018-2023)
  • Table 11. Lung Cancer Screening Software Permanent , by Region USD Million (2018-2023)
  • Table 12. South America Lung Cancer Screening Software, by Country USD Million (2018-2023)
  • Table 13. South America Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 14. South America Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 15. South America Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 16. Brazil Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 17. Brazil Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 18. Brazil Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 19. Argentina Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 20. Argentina Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 21. Argentina Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 22. Rest of South America Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 23. Rest of South America Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 24. Rest of South America Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 25. Asia Pacific Lung Cancer Screening Software, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 27. Asia Pacific Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 28. Asia Pacific Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 29. China Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 30. China Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 31. China Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 32. Japan Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 33. Japan Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 34. Japan Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 35. India Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 36. India Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 37. India Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 38. South Korea Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 39. South Korea Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 40. South Korea Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 41. Taiwan Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 42. Taiwan Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 43. Taiwan Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 44. Australia Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 45. Australia Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 46. Australia Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 50. Europe Lung Cancer Screening Software, by Country USD Million (2018-2023)
  • Table 51. Europe Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 52. Europe Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 53. Europe Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 54. Germany Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 55. Germany Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 56. Germany Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 57. France Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 58. France Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 59. France Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 60. Italy Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 61. Italy Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 62. Italy Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 63. United Kingdom Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 64. United Kingdom Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 65. United Kingdom Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 66. Netherlands Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 67. Netherlands Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 68. Netherlands Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 69. Rest of Europe Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 70. Rest of Europe Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 71. Rest of Europe Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 72. MEA Lung Cancer Screening Software, by Country USD Million (2018-2023)
  • Table 73. MEA Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 74. MEA Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 75. MEA Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 76. Middle East Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 77. Middle East Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 78. Middle East Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 79. Africa Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 80. Africa Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 81. Africa Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 82. North America Lung Cancer Screening Software, by Country USD Million (2018-2023)
  • Table 83. North America Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 84. North America Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 85. North America Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 86. United States Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 87. United States Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 88. United States Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 89. Canada Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 90. Canada Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 91. Canada Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 92. Mexico Lung Cancer Screening Software, by Enterprise USD Million (2018-2023)
  • Table 93. Mexico Lung Cancer Screening Software, by Deployment USD Million (2018-2023)
  • Table 94. Mexico Lung Cancer Screening Software, by Subscription USD Million (2018-2023)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Lung Cancer Screening Software: by Enterprise(USD Million)
  • Table 106. Lung Cancer Screening Software Small and Medium Enterprises , by Region USD Million (2025-2030)
  • Table 107. Lung Cancer Screening Software Large Enterprises , by Region USD Million (2025-2030)
  • Table 108. Lung Cancer Screening Software: by Deployment(USD Million)
  • Table 109. Lung Cancer Screening Software Cloud-Based , by Region USD Million (2025-2030)
  • Table 110. Lung Cancer Screening Software On-Premises , by Region USD Million (2025-2030)
  • Table 111. Lung Cancer Screening Software: by Subscription(USD Million)
  • Table 112. Lung Cancer Screening Software Monthly , by Region USD Million (2025-2030)
  • Table 113. Lung Cancer Screening Software Annual , by Region USD Million (2025-2030)
  • Table 114. Lung Cancer Screening Software Quarterly , by Region USD Million (2025-2030)
  • Table 115. Lung Cancer Screening Software Permanent , by Region USD Million (2025-2030)
  • Table 116. South America Lung Cancer Screening Software, by Country USD Million (2025-2030)
  • Table 117. South America Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 118. South America Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 119. South America Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 120. Brazil Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 121. Brazil Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 122. Brazil Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 123. Argentina Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 124. Argentina Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 125. Argentina Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 126. Rest of South America Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 127. Rest of South America Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 128. Rest of South America Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 129. Asia Pacific Lung Cancer Screening Software, by Country USD Million (2025-2030)
  • Table 130. Asia Pacific Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 131. Asia Pacific Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 132. Asia Pacific Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 133. China Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 134. China Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 135. China Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 136. Japan Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 137. Japan Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 138. Japan Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 139. India Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 140. India Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 141. India Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 142. South Korea Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 143. South Korea Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 144. South Korea Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 145. Taiwan Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 146. Taiwan Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 147. Taiwan Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 148. Australia Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 149. Australia Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 150. Australia Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 153. Rest of Asia-Pacific Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 154. Europe Lung Cancer Screening Software, by Country USD Million (2025-2030)
  • Table 155. Europe Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 156. Europe Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 157. Europe Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 158. Germany Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 159. Germany Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 160. Germany Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 161. France Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 162. France Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 163. France Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 164. Italy Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 165. Italy Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 166. Italy Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 167. United Kingdom Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 168. United Kingdom Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 169. United Kingdom Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 170. Netherlands Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 171. Netherlands Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 172. Netherlands Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 173. Rest of Europe Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 174. Rest of Europe Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 175. Rest of Europe Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 176. MEA Lung Cancer Screening Software, by Country USD Million (2025-2030)
  • Table 177. MEA Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 178. MEA Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 179. MEA Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 180. Middle East Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 181. Middle East Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 182. Middle East Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 183. Africa Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 184. Africa Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 185. Africa Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 186. North America Lung Cancer Screening Software, by Country USD Million (2025-2030)
  • Table 187. North America Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 188. North America Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 189. North America Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 190. United States Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 191. United States Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 192. United States Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 193. Canada Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 194. Canada Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 195. Canada Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 196. Mexico Lung Cancer Screening Software, by Enterprise USD Million (2025-2030)
  • Table 197. Mexico Lung Cancer Screening Software, by Deployment USD Million (2025-2030)
  • Table 198. Mexico Lung Cancer Screening Software, by Subscription USD Million (2025-2030)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lung Cancer Screening Software: by Enterprise USD Million (2018-2023)
  • Figure 5. Global Lung Cancer Screening Software: by Deployment USD Million (2018-2023)
  • Figure 6. Global Lung Cancer Screening Software: by Subscription USD Million (2018-2023)
  • Figure 7. South America Lung Cancer Screening Software Share (%), by Country
  • Figure 8. Asia Pacific Lung Cancer Screening Software Share (%), by Country
  • Figure 9. Europe Lung Cancer Screening Software Share (%), by Country
  • Figure 10. MEA Lung Cancer Screening Software Share (%), by Country
  • Figure 11. North America Lung Cancer Screening Software Share (%), by Country
  • Figure 12. Global Lung Cancer Screening Software share by Players 2023 (%)
  • Figure 13. Global Lung Cancer Screening Software share by Players (Top 3) 2023(%)
  • Figure 14. Global Lung Cancer Screening Software share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. PenRad Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. PenRad Technologies, Inc. (United States) Revenue: by Geography 2023
  • Figure 18. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 19. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2023
  • Figure 20. Kheiron Medical Technologies (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Kheiron Medical Technologies (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Volpara Solutions Limited (New Zeland) Revenue, Net Income and Gross profit
  • Figure 23. Volpara Solutions Limited (New Zeland) Revenue: by Geography 2023
  • Figure 24. Thynk Health (United States) Revenue, Net Income and Gross profit
  • Figure 25. Thynk Health (United States) Revenue: by Geography 2023
  • Figure 26. CRA Health LLC (United States) Revenue, Net Income and Gross profit
  • Figure 27. CRA Health LLC (United States) Revenue: by Geography 2023
  • Figure 28. ProVation Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. ProVation Medical, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Nuance Communications, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Nuance Communications, Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Siemens Healthcare GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Siemens Healthcare GmbH (Germany) Revenue: by Geography 2023
  • Figure 34. CureMetrix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. CureMetrix, Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Global Lung Cancer Screening Software: by Enterprise USD Million (2025-2030)
  • Figure 37. Global Lung Cancer Screening Software: by Deployment USD Million (2025-2030)
  • Figure 38. Global Lung Cancer Screening Software: by Subscription USD Million (2025-2030)
  • Figure 39. South America Lung Cancer Screening Software Share (%), by Country
  • Figure 40. Asia Pacific Lung Cancer Screening Software Share (%), by Country
  • Figure 41. Europe Lung Cancer Screening Software Share (%), by Country
  • Figure 42. MEA Lung Cancer Screening Software Share (%), by Country
  • Figure 43. North America Lung Cancer Screening Software Share (%), by Country
List of companies from research coverage that are profiled in the study
  • PenRad Technologies, Inc. (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • Kheiron Medical Technologies (United Kingdom)
  • Volpara Solutions Limited (New Zeland)
  • Thynk Health (United States)
  • CRA Health LLC (United States)
  • ProVation Medical, Inc. (United States)
  • Nuance Communications, Inc. (United States)
  • Siemens Healthcare GmbH (Germany)
  • CureMetrix, Inc. (United States)
Additional players considered in the study are as follows:
MobileODT (Israel) , Vital Images, Inc (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 243 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lung Cancer Screening Software Market Quantitative research analysis
Global Lung Cancer Screening Software Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as PenRad Technologies, Inc. (United States), Koninklijke Philips N.V. (Netherlands), Kheiron Medical Technologies (United Kingdom), Volpara Solutions Limited (New Zeland), Thynk Health (United States), CRA Health LLC (United States), ProVation Medical, Inc. (United States), Nuance Communications, Inc. (United States), Siemens Healthcare GmbH (Germany) and CureMetrix, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Awareness about Cancer Screening among People " is seen as one of major influencing trends for Lung Cancer Screening Software Market during projected period 2023-2030.
The Lung Cancer Screening Software market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Lung Cancer Screening Software Market Report?

Have a Query? Click Here

Other Related Reports

Intelligent Email Protection Software Comprehensive Study by Type (On-premises, Cloud), Application (SMEs, Large Enterprises), Platform (Android, Windows, Linux, IOS), Industry Vertical (Telecom and ...
$ 3750
Input Method Editor Software Comprehensive Study by Application (PCs, Smartphones/Tablets, TVs, Smart Devices, Others), Enterprise (Small and Medium Enterprises, Large Enterprises), Operating System ...
$ 3450
Labor Management System in Retail Comprehensive Study by Application (Supermarket/Hypermarket, Restaurant Chains, Others), Organisation Size (Large Enterprises, Small and Medium Enterprises (SMEs)), ...
$ 3650
Contractor Safety Management Software Comprehensive Study by Enterprise (Small and Medium Enterprises, Large Enterprises), Deployment (Cloud-based, Web-based), Subscription (Subscription (Annual, Mon...
$ 3350
Social Media Contest Tools Comprehensive Study by Enterprise (Small and Medium Enterprises, Large Enterprises), Deployment (Cloud-based, Web-based), Pricing Model (Subscription (Annual, Monthly, Quar...
$ 3350
Antivirus Software for PC Comprehensive Study by End use (Corporate, Personal), Pricing (Monthly, Annually), Features (Email security, Network security, Cloud security, Cyber security, Others), Opera...
$ 3350